

| Month | Topic 1 |
|---------------|--|
| Jul 2021 | Antibiotic Review 1* (F2) |
| Aug 2021 | HIV Treatment (F2) |
| Sept 2021 | HIV: HIV co-infections: HCV, HBV (A) |
| Oct 2021 | Bacterial: Acinetobacter, Stenotroph (F1) |
| Nov 2021 | Bacterial: Capnocyto, Pasteurella (A) |
| Dec 2021 | Bacterial: Strepto monilliformis/Spirillum minus/Listeria (A) |
| Jan 2022 | Fungal: Histo, Blasto, Cocci, Crypto (A) |
| Feb 2022 | FUO: EBV/Mono, Coxiella (A) |
| Mar 2022 | GI: Inflammatory enteritis (Shigella, E coli, Campy, Amebic) (A) |
| Apr 2022 | GI: Foodborne diseases (B cereus, Listeria, Norovirus, etc) (F2) |
| May 2022 | AFB: MAC, AFB Rapid growers (A) |
| Jun 2022 | Viral: Tropical; Dengue, Chikungunya, Yellow Fever (A) |
| Jul 2022 | Antibiotic review 1* (F1) |
| Aug 2022 | HIV: Treatment (F2) |
| Sept 2022 | Immunocompromised host: BK, HHV 6,7, CMV (A) |
| Oct 2022 | Immunocompromised host: TNF inhibitor-assoc infections (F2) |
| Nov 2022 | Parasites: Trematodes / Cestodes (F1) |
| Dec 2022 | Pregnancy: Endometritis, Fever/pregnancy (A) |
| Jan 2023 | Viral: Dengue, Chikungunya, Yellow Fever (A) |
| Feb 2023 | Respiratory Infections: Influenza, RSV, Metapneumovirus (F2) |
| Mar 2023 | Sepsis: Leptospirosis, Rickettsia (A) |
| Apr 2023 | Sepsis: Post-splenectomy infections (F2) |
| May 2021/2023 | Surgical: Burn Infections, Bites (A) |
| Jun 2021/2023 | Surgical: CSF shunt infections (F2) |

*beta-lactams, monobactam

**vancomycin, linezolid, daptomycin; carbapenems, aminoglycosides; tetracyclines, macrolides, T

KEY: A = Attending F1 = First Year Fellow F2 = 2nd Year Fellow

| Topic 2 | IDBR Dates |
|---|------------|
| Antibiotic Review 2** (F1) | |
| HIV: neurologic and renal complications of HIV (F1) | |
| HIV: HIV-associated malignancies (F2) 9/15 | |
| Bacterial: Borrellia / Bordetella (A) LLOYD | |
| Bacterial: Erysipelothrix / Bacillus sp (F2) | |
| Fungal: Candida, Aspergillus, Mucor (F1) | |
| FUO: Bartonella, francisella, brucella (F1) | |
| GI: C diff (F2) | |
| GI: Enteric fever (Salmonella, Yersinia, C fetus, typhoidal tularemia) (F1) | |
| AFB: TB, MDR TB (A) | |
| AFB: Extra-pulm TB, TB-HIV (A) | |
| Viral: encephalitis; HSV1/2, VZV, West Nile virus, measles, etc (A) | |
| Antibiotic Review 2** (F2) | |
| HIV: Opportunistic Infections (F1) | |
| Immunocompromised host: Nocardia, Parvo, EBV (A) | |
| Parasites: Nematodes, Amoeba & Cyclospora (A) | |
| Parasites: Trypanosoma, Toxoplasma/Protozoa (A) | |
| Pregnancy: Septic thrombophlebitis, pyelo (F2) | |
| Respiratory Infections: Chlamydia psittaci / C pneumoniae / C diphtheria (F1) | |
| Respiratory Infections: Legionella/atypicals, Lung abscess (A) | |
| Sepsis: Meningitis (Neisseria) (F1) | |
| Sepsis: Staph/Strept TSS (A) | |
| Surgical: Intra-Abd Infections (F1) | |
| Surgical: Ortho & vascular device infections (A) | |

MP-SX, fluoroquinolones, metronidazole, clindamycin